AIM ImmunoTech Inc. 10-Q

ITEM 5: Other Information Director and Executive Officer Trading During the quarter ended June 30, 2026, no director or officer adopted or terminated any Rule 10b5-1 or non-Rule 10b5-1 trading arrangements (as defined in Item 408 of Regulation S-K). 51 ITEM 6: Exhibits Exhibit No. Description 3.1 Certificate of Incorporation as Amended and Restated through June 10, 2025 (incorporated by reference to Exhibit 3.1(i) to the Company’s Current Report on Form 8-K filed with the SEC on October 29, 2025). 3.2 Amended and Restated By-Laws of Registrant (incorporated by reference to Exhibit 3.7(ii) to the Company’s Current Report on Form 8-K filed with the SEC on February 26, 2025). 3.3 Certificate of Designation of Series G Preferred Stock (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed with the SEC on March 6, 2026). 3.4 Amendment to the Company’s Amended and Restated By-Laws dated June 9, 2026 (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K (File No. 001-27072) filed with the SEC on June 10, 2026). 10.1 Amendment to Equity Distribution Agreement with Maxim Group, LLC dated April 10, 2026 (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed with the SEC on April 10, 2026). 10.2 Amendment #2 to Promissory Note with Streeterville Capital, LLC dated May 18, 2026 (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K (File No. 001-27072) filed with the SEC on May 19, 2026). 10.3 Placement Agency Agreement with Ladenburg Thalman & Co, Inc dated May 20, 2026 (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K (File No. 001-27072) filed with the SEC on May 21, 2026). 10.4 Security Purchase Agreement with Institution Investors dated June 9, 2026 (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K (File No. 001-27072) filed with the SEC on June 11, 2026). 10.5 Placement Agency Agreement with Ladenburg Thalmann dated June 9, 2026 (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K (File No. 001-27072) filed with the SEC on June 11, 2026). 10.6 Amendment to the Company’s Amended and Restated By-Laws dated June 9, 2026 (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K (File No. 001-27072) filed with the SEC on June 10, 2026). 10.7 Mutual Termination of Controlled Equity Distribution Agreement dated April 1, 2025 effective August 15,2026 signed July 31, 2026 with Maxim Group, LLC*# 10.8 Proposal to GMP Manufacture Poly I and Poly C12U with Sterling Pharma Solutions dated July 31, 2026 (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K (File No. 001-27072) filed with the SEC on August 6, 2026). 31.1 Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 from the Company’s Chief Executive Officer. * 31.2 Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 from the Company’s Chief Financial Officer. * 32.1 Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 from the Company’s Chief Executive Officer. ** 32.2 Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 from the Company’s Chief Financial Officer. ** 101.INS Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. * Filed herewith. ** The certifications attached as Exhibit 32.1 and 32.2 that accompany this Quarterly Report on Form 10-Q are deemed furnished and not filed with the Securities and Exchange Commission. # Pursuant to Item 601(b)(10) of Regulation S-K, certain confidential portions of this exhibit were omitted by means of marking such portions with an asterisk because the identified confidential portions (i) are not material and (ii) are the type that the Company treats as private or confidential. The Company hereby agrees to furnish a copy of any redacted portion to the SEC upon request. 52 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. AIM IMMUNOTECH INC. /s/ Thomas K. Equels Thomas K. Equels, Esq. Chief Executive Officer & President /s/ Robert Dickey IV Robert Dickey IV Chief Financial Officer Date: August 7, 2026 53